^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Molecular resistance mechanisms of ALK inhibitors and implications for therapeutic management of ALK-rearranged lung cancer patients

Published date:
02/24/2017
Excerpt:
In this study crizotinib resistance mutations were confirmed in 11 (20%, N=51) specimens from biopsy sites that included pleural fluid (31%), liver (22%), and nodal tissue (18%) from 10 patients….Other mutations (frequency) detected were C1156Y (2%), G1202R (2%), I1171T (2%), S1206Y (2%), and E1210K (2%).
DOI:
10.21037/tcr.2017.03.22